Epizyme (NASDAQ:EPZM) Rating Increased to Sell at BidaskClub

Epizyme (NASDAQ:EPZM) was upgraded by stock analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Saturday, BidAskClub reports.

EPZM has been the subject of a number of other reports. SVB Leerink decreased their target price on shares of Epizyme from $18.00 to $16.00 and set a “market perform” rating for the company in a research note on Friday, June 19th. Morgan Stanley decreased their target price on shares of Epizyme from $31.00 to $29.00 and set an “overweight” rating for the company in a research note on Wednesday, August 5th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $27.00.

EPZM stock opened at $13.26 on Friday. The stock has a market capitalization of $1.32 billion, a PE ratio of -6.38 and a beta of 1.92. Epizyme has a 12-month low of $9.73 and a 12-month high of $27.82. The company has a current ratio of 11.57, a quick ratio of 11.25 and a debt-to-equity ratio of 0.27. The stock’s 50 day simple moving average is $12.76 and its 200 day simple moving average is $16.12.

Epizyme (NASDAQ:EPZM) last released its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.02). The business had revenue of $2.47 million during the quarter, compared to the consensus estimate of $4.67 million. Epizyme had a negative net margin of 1,459.72% and a negative return on equity of 72.65%. On average, research analysts predict that Epizyme will post -2.33 earnings per share for the current year.

In related news, Director David M. Mott acquired 62,019 shares of Epizyme stock in a transaction dated Friday, June 26th. The stock was purchased at an average cost of $16.03 per share, for a total transaction of $994,164.57. Following the purchase, the director now directly owns 82,601 shares of the company’s stock, valued at approximately $1,324,094.03. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Robert B. Bazemore sold 4,773 shares of the company’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $16.15, for a total value of $77,083.95. Following the completion of the sale, the chief executive officer now owns 254,871 shares of the company’s stock, valued at $4,116,166.65. The disclosure for this sale can be found here. Insiders sold a total of 7,866 shares of company stock valued at $123,754 over the last 90 days. 16.30% of the stock is currently owned by company insiders.

Several large investors have recently bought and sold shares of the company. Redmile Group LLC increased its stake in Epizyme by 0.3% in the 1st quarter. Redmile Group LLC now owns 8,768,475 shares of the biopharmaceutical company’s stock worth $135,999,000 after buying an additional 22,442 shares in the last quarter. Vanguard Group Inc. increased its stake in Epizyme by 3.2% in the 2nd quarter. Vanguard Group Inc. now owns 7,210,960 shares of the biopharmaceutical company’s stock worth $115,808,000 after buying an additional 223,768 shares in the last quarter. FMR LLC increased its stake in Epizyme by 0.3% in the 1st quarter. FMR LLC now owns 3,484,137 shares of the biopharmaceutical company’s stock worth $43,169,000 after buying an additional 11,759 shares in the last quarter. State Street Corp increased its stake in Epizyme by 1.3% in the 1st quarter. State Street Corp now owns 2,494,910 shares of the biopharmaceutical company’s stock worth $38,696,000 after buying an additional 30,834 shares in the last quarter. Finally, Victory Capital Management Inc. increased its stake in Epizyme by 5.4% in the 2nd quarter. Victory Capital Management Inc. now owns 2,296,110 shares of the biopharmaceutical company’s stock worth $36,875,000 after buying an additional 118,026 shares in the last quarter. Hedge funds and other institutional investors own 90.93% of the company’s stock.

About Epizyme

Epizyme, Inc, a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors.

Read More: Market Capitalization

Analyst Recommendations for Epizyme (NASDAQ:EPZM)

Receive News & Ratings for Epizyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme and related companies with MarketBeat.com's FREE daily email newsletter.